Compound has potential for new class of AIDS drugsMay 15, 2008ANN ARBOR, Mich.-Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs. Researchers at the University of Michigan used computer models to develop the inhibiting compound, and then confirmed in the lab that the compound does indeed inhibit HIV protease, which is an established target for AIDS treatment. The protease is necessary to replicate the virus, says Heather Carlson, U-M professor of medicinal chemistry and principal investigator of the study. Carlson stresses this is a preliminary step, but still significant.
"It's very easy to make an inhibitor, (but) it's very hard to make a drug," said Carlson, who also has an appointment in chemistry. "This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism." What's so exciting is how differently that mechanism works from the current drugs used to keep the HIV from maturing and replicating, she says. Current drugs called protease inhibitors work by debilitating the HIV-1 protease. This does the same, but in a different way, Carlson says. A protease is an enzyme that clips apart proteins, and in the case of HIV drugs, when the HIV-1 protease is inhibited it cannot process the proteins required to assemble an active virus. In existing treatments, a larger molecule binds to the center of the protease, freezing it closed. The new mechanism targets a different area of the HIV-1 protease, called the flap recognition pocket, and actually holds the protease open. Scientists knew the flaps opened and closed, but didn't know how to target that as a mechanism, Carlson says. Carlson's group discovered that this flap, when held open by a very small molecule-half the size of the ones used in current drug treatments-also inhibits the protease. In addition to a new class of drugs, the compound is key because smaller molecules have better drug-like properties and are absorbed much more easily. "This new class of smaller molecules could have better drug properties (and) could get around current side effects," Carlson said. "HIV dosing regimes are really difficult. You have to take medicine several times in the day. Maybe you wouldn't have to do that with these smaller molecules because they would be absorbed differently." Kelly Damm, a former student and now at Johnson & Johnson, initially had the idea to target the flaps in this new way, Carlson says. "In a way, this works like a door jam. If you looked only at the door when it's shut, you'd not know you could put a jam in it," she said. "We saw a spot where we could block the closing event, but because everyone else was working with the closed form, they couldn't see it." University of Michigan Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Secondhand Smoke Beta Cells life on Mars Hubble Space Telescope Archaea Radiation Treatment Enzymes Amputation Ecosystem Cosmic Rays Ecosystems Biomarkers Multiple Myeloma Morphine Saturns Rings Leukaemia Bipolar Disorder AIDS vaccine Explosives Mangrove Palliative Care Neutron Aurora Cancer Cells Cancer Therapy
See More: Science News Tags | |||||||||||||||||||||
|
Related Protease Current Events and Protease News Articles New study reveals structure of the HIV protein shell New research by scientists at The Scripps Research Institute and other institutions provides a close-up look at the cone-shaped shell that is the hallmark of human immunodeficiency virus (HIV), revealing how it is held together-and possible ways to break it apart. What is the role of reactive oxygen species in ethanol-mediated cell death of polarized hepatic cells? Liver disease that results as a consequence of alcohol abuse is a major medical problem worldwide. Ethanol consumption leads to a variety of liver alterations including the accumulation of fat, inflammation of the liver, as well as the presence of scar tissue. NEJM Study Points to New Era in Hepatitis C Treatment For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone. Enzyme involved in inflammatory bowel disease discovered at Penn State College of Medicine Researchers at Penn State College of Medicine, working with biochemists, geneticists and clinicians at the University of Bern, Switzerland and in the United Kingdom, have discovered an enzyme that has a key role in inflammatory bowel disease (IBD). Mayo Clinic researchers find agents that speed up destruction of proteins linked to Alzheimer's Taking a new approach to the treatment and prevention of Alzheimer's disease, a research team led by investigators at the Mayo Clinic campus in Florida has shown that druglike compounds can speed up destruction of the amyloid beta (A-beta) proteins that form plaque in the brains of patients with the disorder. Locking Parasites in Host Cell Could Be New Way to Fight Malaria, Penn Study Shows Researchers at the University of Pennsylvania have discovered that parasites hijack host-cell proteins to ensure their survival and proliferation, suggesting new ways to control the diseases they cause. HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection Researchers at the Tulane University School of Medicine, New Orleans, Louisiana have discovered that the HIV-1 protease inhibitors (PIs), such as nelfinavir included in highly active antiretroviral therapy (HAART) regimen for the treatment of HIV-1 patients, induce deleterious effects on insulin secretion mediated through the oxidative stress pathway. Cathepsin B increases apoptosis in fulminant hepatic failure The traditional view is that hepatocyte necrosis is the main feature of fulminant hepatic failure, but increasing evidence implicates a dominant role for hepatocyte apoptosis in this pathogenesis. New Stanford list of HIV mutations vital to tracking AIDS epidemic In a collaborative study with the World Health Organization and seven other laboratories, researchers at the Stanford University School of Medicine have compiled a list of 93 common mutations of the AIDS virus associated with drug resistance that will be used to track future resistance trends throughout the world. New information points to safer methadone use for treatment of pain and addiction New findings may significantly improve the safety of methadone, a drug widely used to treat cancer pain and addiction to heroin and other opioid drugs, according to researchers at Washington University School of Medicine in St. Louis and the University of Washington in Seattle. More Protease Current Events and Protease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||